Multidrug resistance protein 4 (MRP4/ABCC4) regulates thrombus formation in vitro and in vivo

Area of Science:

• Hematology
• Molecular Biology
• Pharmacology

Background:

• The multidrug resistance protein 4 (MRP4) transporter plays a role in platelet function by removing cyclic nucleotides and uptaking ADP.
• The direct involvement of MRP4 in platelet activation mechanisms remains incompletely understood.
• Investigating MRP4's role is crucial for understanding platelet signaling and developing new antithrombotic strategies.

Purpose of the Study:

• To elucidate the detailed mechanisms by which MRP4 regulates platelet activation.
• To determine if MRP4 inhibition impacts platelet aggregation, signaling pathways, and thrombus formation.
• To assess the therapeutic potential of MRP4 inhibition in thromboembolic disorders.

Main Methods:

• Utilized the MRP4 inhibitor MK571 and various signaling pathway inhibitors (H89, SQ22536, ODQ) to study collagen-induced platelet aggregation.
• Assessed ATP release, calcium mobilization, and protein phosphorylation (PKC, JNK, Akt) following MK571 treatment.
• Employed PFA-100 device and in vivo mouse mesenteric venule models to evaluate platelet plug and thrombus formation.
• Conducted electron spin resonance experiments to measure hydroxyl radical formation.

Main Results:

• MK571 significantly inhibited collagen-induced platelet aggregation, ATP release, and calcium mobilization.
• MK571 partially reversed PKA inhibition, indicating a pathway independent of cyclic nucleotide production.
• Inhibition of PKC, JNK, and Akt phosphorylation, alongside reduced hydroxyl radical formation, was observed with MK571.
• MK571 demonstrated efficacy in delaying platelet plug formation in vitro and thrombus formation in vivo.

Conclusions:

• MRP4 inhibition effectively prevents platelet activation and thrombus formation through mechanisms beyond cyclic nucleotide transport.
• MK571's effects on platelet activation warrant further investigation into potential off-target effects (MRP1, LTD4 receptor).
• MRP4 emerges as a promising therapeutic target for managing thromboembolic diseases.